

Shyamasundaran Kottlil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1182993/publications.pdf>

Version: 2024-02-01

151
papers

5,890
citations

117453

34
h-index

85405

71
g-index

157
all docs

157
docs citations

157
times ranked

8290
citing authors

#	ARTICLE	IF	CITATIONS
1	Programmed death 1 expressing CD8+CXCR5+ follicular T cells constitute effector rather than exhaustive phenotype in patients with chronic hepatitis B. <i>Hepatology</i> , 2022, 75, 690-708.	3.6	10
2	Use of oral polio vaccine and the incidence of COVID-19 in the world. <i>PLoS ONE</i> , 2022, 17, e0265562.	1.1	17
3	Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 611-621.	4.6	22
4	Toward demystifying HIV as a risk factor for coronavirus disease 2019 complications. <i>Aids</i> , 2022, 36, 749-750.	1.0	0
5	The Enhanced Liver Fibrosis Index Predicts Hepatic Fibrosis Superior to FIB4 and APRI in HIV/HCV Infected Patients. <i>Clinical Infectious Diseases</i> , 2021, 73, 450-459.	2.9	10
6	A Model of Care Optimized for Marginalized Remote Population Unravels Migration Pattern in India. <i>Hepatology</i> , 2021, 73, 1261-1274.	3.6	2
7	Higher Levels of Fibrosis in a Cohort of Veterans with Chronic Viral Hepatitis are Associated with Extrahepatic Cancers. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 195-200.	0.4	7
8	Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant. <i>American Journal of Transplantation</i> , 2021, 21, 1780-1788.	2.6	14
9	Evolution of Nipah Virus Infection: Past, Present, and Future Considerations. <i>Tropical Medicine and Infectious Disease</i> , 2021, 6, 24.	0.9	33
10	Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 169-184.	3.7	24
11	Hepatitis C Virus Relapse After Ultrashort Direct-Acting Antiviral Therapy Associates With Expression of Genes Involved With Natural Killer-Cell and CD8+ T-Cell Function. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab118.	0.4	1
12	Hepatitis E Infection in a Longitudinal Cohort of HCV and HCV/HIV Coinfected Persons. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 534-541.	0.5	2
13	Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5497.	1.8	55
14	Potential Use of Adjuvant Bacteriophage Therapy With Debridement, Antibiotics, and Implant Retention Surgery to Treat Chronic Prosthetic Joint Infections. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab277.	0.4	16
15	Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?. <i>Cells</i> , 2021, 10, 1097.	1.8	39
16	Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	69
17	Oral Polio Vaccine to Protect Against COVID-19: Out of the Box Strategies?. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab367.	0.4	7
18	Follicular Helper T (TFH) Cell Targeting by TLR8 Signaling For Improving HBsAg-Specific B Cell Response In Chronic Hepatitis B Patients. <i>Frontiers in Immunology</i> , 2021, 12, 735913.	2.2	20

#	ARTICLE	IF	CITATIONS
19	Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1614-1623.	1.0	2
20	Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis. <i>Viruses</i> , 2021, 13, 1831.	1.5	3
21	CCR5+ T-Cells Homed to the Liver Exhibit Inflammatory and Profibrogenic Signatures in Chronic HIV/HCV-Coinfected Patients. <i>Viruses</i> , 2021, 13, 2074.	1.5	1
22	Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management. <i>Frontiers in Medicine</i> , 2021, 8, 752875.	1.2	24
23	Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans. <i>Viruses</i> , 2021, 13, 2400.	1.5	7
24	COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine. <i>JAMA Network Open</i> , 2021, 4, e2135044.	2.8	18
25	Hepatitis C Core Antigen Testing: Still an Effective Diagnostic Method for Global Elimination of Hepatitis C. <i>Clinical Infectious Diseases</i> , 2020, 70, 674-675.	2.9	5
26	Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4- \uparrow G and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 102-109.	1.9	6
27	Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2020, 38, 233-242.	1.7	19
28	Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7473.	1.8	7
29	Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. <i>BMC Infectious Diseases</i> , 2020, 20, 929.	1.3	3
30	PNPLA3 polymorphisms are associated with raised alanine aminotransferase levels in hepatitis C virus genotype 3. <i>Arab Journal of Gastroenterology</i> , 2020, 21, 267-272.	0.4	0
31	Advances in hepatitis B therapeutics. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612096502.	1.1	26
32	Abnormal Innate Immunity in Acute-on-Chronic Liver Failure: Immunotargets for Therapeutics. <i>Frontiers in Immunology</i> , 2020, 11, 2013.	2.2	20
33	Immune Correlates of COVID-19 Control. <i>Frontiers in Immunology</i> , 2020, 11, 569611.	2.2	21
34	DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic Hepatitis B Virus or Hepatitis C Virus, with or without Human Immunodeficient Virus Co-infection. <i>Clinical Infectious Diseases</i> , 2020, 73, e184-e190.	2.9	13
35	Reconstitution of T follicular helper-humoral immune axis with elimination of hepatitis C virus. <i>Scientific Reports</i> , 2020, 10, 19924.	1.6	4
36	Can existing live vaccines prevent COVID-19?. <i>Science</i> , 2020, 368, 1187-1188.	6.0	92

#	ARTICLE	IF	CITATIONS
37	The Effect of GSâ€548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANSâ€6637 in Healthy Adults. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1598-1605.	1.0	0
38	Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients. <i>Scientific Reports</i> , 2020, 10, 1835.	1.6	44
39	IL-21â€Deficient T Follicular Helper Cells Support B Cell Responses Through IL-27 in Patients With Chronic Hepatitis B. <i>Frontiers in Immunology</i> , 2020, 11, 599648.	2.2	14
40	Hepatitis A. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 191-199.	1.0	53
41	Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays. <i>PLoS ONE</i> , 2020, 15, e0237828.	1.1	67
42	Safety, Pharmacokinetics and Pharmacodynamics of Selgantolimod, an Oral Toll-Like Receptor 8 Agonist: A Phase Ia Study in Healthy Subjects. <i>Antiviral Therapy</i> , 2020, 25, 171-180.	0.6	12
43	Sofosbuvir/Velpatasvir/Voxilaprevir: A Highly Effective Option for Retreatment of Hepatitis C in Difficult-to-treat Patients. <i>Antiviral Therapy</i> , 2019, 24, 1-10.	0.6	8
44	Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. <i>Proteomics - Clinical Applications</i> , 2019, 13, 1800006.	0.8	1
45	What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism. <i>Patient</i> , 2019, 12, 631-638.	1.1	17
46	Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 794-804.	3.7	68
47	Peripheral PD-1+ T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1470.	2.2	14
48	Implementation of a unique hepatitis C care continuum model in Rwanda. <i>Journal of Public Health</i> , 2019, 41, e203-e208.	1.0	5
49	HIV and HCV augments inflammatory responses through increased TREM-1 expression and signaling in Kupffer and Myeloid cells. <i>PLoS Pathogens</i> , 2019, 15, e1007883.	2.1	42
50	Long-Term Changes in Hepatic Fibrosis following Hepatitis C Viral Clearance in Patients with and without HIV. <i>Antiviral Therapy</i> , 2019, 24, 451-457.	0.6	9
51	Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance. <i>Clinical Infectious Diseases</i> , 2019, 69, 571-576.	2.9	17
52	A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). <i>Journal of Hepatology</i> , 2019, 71, 498-504.	1.8	20
53	Persistent gamma delta Tâ€cell dysfunction in chronic HCV infection despite directâ€acting antiviral therapy induced cure. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1105-1116.	1.0	20
54	Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients. <i>Hepatology International</i> , 2019, 13, 270-276.	1.9	22

#	ARTICLE	IF	CITATIONS
55	2897. Collocated Buprenorphine Is Associated with Improved HCV Visit Adherence in People Who Inject Drugs (PWID): Data From the ANCHOR Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S82-S82.	0.4	2
56	2900. High Rates of Experienced and Witnessed Opioid Overdose in PWID Receiving HCV Treatment: Data From the ANCHOR Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S83-S83.	0.4	1
57	298. Collocation of Hepatitis C Care Continuum with MAT for High-Prevalence, High-Risk Population. <i>Open Forum Infectious Diseases</i> , 2019, 6, S161-S161.	0.4	1
58	Clinical features and determinants of chronicity in hepatitis E virus infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 414-421.	1.0	35
59	Characterization of changes in intrahepatic immune cell populations during <sc>HCV</sc> treatment with sofosbuvir and ribavirin. <i>Journal of Viral Hepatitis</i> , 2019, 26, 323-328.	1.0	6
60	Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade. <i>Clinical Infectious Diseases</i> , 2019, 68, 1911-1918.	2.9	17
61	Quantification of Hepatitis B Surface Antigen: Is there a Role in HIV-Hepatitis B Virus Coinfection?. <i>AIDS Reviews</i> , 2019, 21, 175-183.	0.5	0
62	Quantification of Hepatitis B Surface Antigen: Is there a Role in HIV-Hepatitis B Virus Coinfection?. <i>AIDS Reviews</i> , 2019, 21, .	0.5	0
63	No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV. <i>Journal of Infectious Diseases</i> , 2018, 217, 47-50.	1.9	33
64	Time to end treatment restrictions for people with hepatitis C who inject drugs. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 142-143.	3.7	2
65	Chronic Hepatitis B Infection. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1802.	3.8	473
66	Recovery of hepatitis C specific Tâ€cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis. <i>Journal of Medical Virology</i> , 2018, 90, 936-941.	2.5	5
67	Mechanisms of neuropathogenesis in HIV and HCV: similarities, differences, and unknowns. <i>Journal of NeuroVirology</i> , 2018, 24, 670-678.	1.0	7
68	Expansion of Treatment for Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2018, 168, 457.	2.0	0
69	Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C. <i>Interdisciplinary Perspectives on Infectious Diseases</i> , 2018, 2018, 1-9.	0.6	4
70	HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis. <i>Scientific Reports</i> , 2018, 8, 15296.	1.6	33
71	Treatment of Chronic Hepatitis B Infectionâ€Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1202.	3.8	0
72	Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. <i>Hepatology International</i> , 2018, 12, 214-222.	1.9	20

#	ARTICLE	IF	CITATIONS
73	Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV. <i>Circulation</i> , 2018, 138, 1100-1112.	1.6	541
74	Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-7.	0.7	18
75	Shortening Treatment for Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2018, 14, 186-188.	0.2	1
76	Race or genetic makeup for hepatitis C virus treatment decisions?. <i>Hepatology</i> , 2017, 65, 2124-2125.	3.6	18
77	miRNA signatures can predict acute liver failure in hepatitis E infected pregnant females. <i>Heliyon</i> , 2017, 3, e00287.	1.4	14
78	Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. <i>Liver International</i> , 2017, 37, 1796-1804.	1.9	30
79	Are we nearing the end in the fight against hepatitis C?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 499-500.	1.4	5
80	Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 6-12.	2.9	133
81	Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. <i>Hepatology International</i> , 2017, 11, 161-170.	1.9	26
82	A pilot study to expand treatment of chronic hepatitis C in resource-limited settings. <i>Antiviral Research</i> , 2017, 146, 184-190.	1.9	11
83	Vedoprevir in the management of hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1399-1402.	1.9	2
84	Shortening the duration of therapy for chronic hepatitis C infection. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 832-836.	3.7	35
85	Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers. <i>Annals of Internal Medicine</i> , 2017, 167, 311.	2.0	192
86	Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. <i>Hepatology Communications</i> , 2017, 1, 586-594.	2.0	36
87	IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir. <i>Gastroenterology</i> , 2017, 153, 1694-1695.	0.6	19
88	Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 118-124.	1.0	8
89	Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. <i>Clinical Microbiology Reviews</i> , 2017, 30, 23-42.	5.7	10
90	Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection. <i>Hepatology International</i> , 2017, 11, 152-160.	1.9	13

#	ARTICLE	IF	CITATIONS
91	Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection. <i>Transplantation Direct</i> , 2017, 3, e229.	0.8	4
92	Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. <i>BioMed Research International</i> , 2017, 2017, 1-8.	0.9	29
93	Factors associated with high cardiovascular risk in a primarily African American, urban HIV-infected population. <i>SAGE Open Medicine</i> , 2017, 5, 205031211772564.	0.7	1
94	Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis. <i>PLoS ONE</i> , 2017, 12, e0188314.	1.1	2
95	On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series. <i>Case Reports in Infectious Diseases</i> , 2016, 2016, 1-4.	0.2	1
96	Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. <i>Liver International</i> , 2016, 36, 1783-1792.	1.9	79
97	Systemic manifestations of hepatitis C infection. <i>Infectious Agents and Cancer</i> , 2016, 11, 29.	1.2	40
98	Eradication Strategies for Chronic Hepatitis B Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, S318-S325.	2.9	13
99	Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis. <i>Hepatology International</i> , 2016, 10, 937-946.	1.9	12
100	Treatment of hepatitis C in renal impairment and renal transplant. <i>Current Treatment Options in Infectious Diseases</i> , 2016, 8, 438-448.	0.8	0
101	Treatment of hepatitis B virus: an update. <i>Future Microbiology</i> , 2016, 11, 1581-1597.	1.0	27
102	Contribution of antiretroviral therapy to cardiovascular disease risk in HIV-infected patients. <i>Future Virology</i> , 2016, 11, 509-527.	0.9	2
103	Hepatitis C genotype 3 disease. <i>Hepatology International</i> , 2016, 10, 861-870.	1.9	26
104	High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. <i>Hepatology International</i> , 2016, 10, 310-319.	1.9	60
105	No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA $\leq 6,000,000$ IU/mL. <i>Hepatology</i> , 2016, 63, 28-30.	3.6	32
106	Sofosbuvir and ledipasvir for HIV/HCV co-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 743-749.	0.9	11
107	Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. <i>Clinical Infectious Diseases</i> , 2016, 62, 280-288.	2.9	49
108	Sofosbuvir and velpatasvir: a stellar option for patients with decompensated hepatitis C virus (HCV) cirrhosis. <i>Annals of Translational Medicine</i> , 2016, 4, S8-S8.	0.7	4

#	ARTICLE	IF	CITATIONS
109	Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment. <i>World Journal of Hepatology</i> , 2016, 8, 1318.	0.8	19
110	Newer therapeutics for hepatitis C. <i>Annals of Translational Medicine</i> , 2016, 4, 31.	0.7	0
111	Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection. <i>Annals of Internal Medicine</i> , 2015, 163, 899-907.	2.0	53
112	Persistently elevated abnormal Bâ€cell subpopulations and antiâ€core antibodies in patients coâ€infected with HIV/HCV who relapse. <i>Journal of Medical Virology</i> , 2015, 87, 544-552.	2.5	3
113	Treatment of hepatitis C in patients with HIV. <i>Lancet HIV</i> , 2015, 2, e308-e309.	2.1	4
114	Durable Sustained Virologic Response After Oral Directly Acting Antiviral Therapy Despite Immunosuppressive Treatment. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv091.	0.4	7
115	Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. <i>PLoS ONE</i> , 2015, 10, e0133236.	1.1	33
116	Sofosbuvir for treatment of chronic hepatitis C. <i>Hepatology International</i> , 2015, 9, 161-173.	1.9	29
117	Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. <i>Lancet, The</i> , 2015, 385, 1107-1113.	6.3	148
118	Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy. <i>Clinical Infectious Diseases</i> , 2015, 60, 1743-1751.	2.9	91
119	Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1â€infected patients. <i>Hepatology</i> , 2015, 61, 790-801.	3.6	128
120	Reply to Harrington et al. <i>Clinical Infectious Diseases</i> , 2015, 61, 667-668.	2.9	2
121	Drug-Drug Interactions in Patients Co-infected With HCV and HIVâ€Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 186.	3.8	3
122	Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. <i>Lancet Infectious Diseases, The</i> , 2015, 15, 1049-1054.	4.6	148
123	Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1232.	3.8	186
124	Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Antiâ€Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. <i>Clinical Infectious Diseases</i> , 2015, 62, civ897.	2.9	31
125	Hepatitis C-Associated Mixed Cryoglobulinemic Vasculitis Induces Differential Gene Expression in Peripheral Mononuclear Cells. <i>Frontiers in Immunology</i> , 2014, 5, 248.	2.2	6
126	Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse. <i>Annals of Internal Medicine</i> , 2014, 161, 634.	2.0	68

#	ARTICLE	IF	CITATIONS
127	Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C. <i>Hepatology International</i> , 2014, 8, 560-566.	1.9	9
128	Treatment of Hepatitis C. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 631.	3.8	390
129	Assessment of Outcomes of Hepatitis C Treatment—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2571.	3.8	2
130	Mechanisms of alcohol-induced hepatocellular carcinoma. <i>Hepatology International</i> , 2014, 8, 452-457.	1.9	27
131	IFNL4-Î”G Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin. <i>Journal of Infectious Diseases</i> , 2014, 209, 1700-1704.	1.9	74
132	Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. <i>Journal of Clinical Investigation</i> , 2014, 124, 3352-3363.	3.9	179
133	Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 804.	3.8	265
134	High interferon-Î”stimulated gene ISGÎ”15 expression affects HCV treatment outcome in patients co-infected with HIV and HCV. <i>Journal of Medical Virology</i> , 2013, 85, 959-963.	2.5	13
135	MicroRNA Expression Profiling in HCV-Infected Human Hepatoma Cells Identifies Potential Anti-Viral Targets Induced by Interferon-Î”. <i>PLoS ONE</i> , 2013, 8, e55733.	1.1	61
136	Human immunodeficiency virus enhances hepatitis C virus replication by differential regulation of IFN and TGF family genes. <i>Journal of Medical Virology</i> , 2012, 84, 1344-1352.	2.5	7
137	Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: Impaired viral kinetics and therapeutic response. <i>Hepatology</i> , 2012, 56, 444-454.	3.6	61
138	Hepatitis C Virus Infection and Coinfection With Human Immunodeficiency Virus. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 294-301.	3.8	41
139	B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. <i>Blood</i> , 2010, 116, 5571-5579.	0.6	234
140	HCV in peripheral blood mononuclear cells are predominantly carried on the surface of cells in HIV/HCV co-infected individuals. <i>Journal of Medical Virology</i> , 2010, 82, 2032-2037.	2.5	21
141	Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. <i>Hepatology</i> , 2009, 50, 34-45.	3.6	44
142	Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis. <i>Hepatology Research</i> , 2009, 39, 1178-1189.	1.8	10
143	HIV/AIDS Reviews. <i>Journal of Urban Health</i> , 2008, 85, 6-10.	1.8	0
144	Innate Immunity in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 151-159.	0.9	33

#	ARTICLE	IF	CITATIONS
145	Innate Immune Dysfunction in HIV Infection: Effect of HIV Envelope-NK Cell Interactions. Journal of Immunology, 2006, 176, 1107-1114.	0.4	62
146	Hepatitis B & hepatitis C in HIV-infection. Indian Journal of Medical Research, 2005, 121, 424-50.	0.4	6
147	Changes in Hepatitis C Viral Response After Initiation of Highly Active Antiretroviral Therapy and Control of HIV Viremia in Chronically Co-infected Individuals. HIV Clinical Trials, 2004, 5, 25-32.	2.0	11
148	Innate Immunity in Human Immunodeficiency Virus Infection: Effect of Viremia on Natural Killer Cell Function. Journal of Infectious Diseases, 2003, 187, 1038-1045.	1.9	151
149	Natural killer cells in HIV-1 infection: role of NK cell-mediated non-cytolytic mechanisms in pathogenesis of HIV-1 infection. Indian Journal of Experimental Biology, 2003, 41, 1219-25.	0.5	7
150	Human immunodeficiency virus type 1 replication, immune activation, and circulating cytotoxic T cells against uninfected CD4+ T cells. Journal of Clinical Immunology, 2000, 20, 175-186.	2.0	8
151	Case Report and Review of Management of HIV/HCV Coinfection After Treatment Failure. Current Treatment Options in Infectious Diseases, 0, , .	0.8	0